公开(公告)号：US20180356373A1

公开(公告)日：2018-12-13

申请号：US15621973

申请日：2017-06-13

申请人： Velayudhan Sahadevan

发明人： Velayudhan Sahadevan

IPC分类号： G01N30/02 ,  C12N15/113 ,  C12N15/63 ,  C12Q1/68 ,  G01N30/04

CPC分类号： G01N30/02 ,  A61K48/00 ,  A61N5/00 ,  C12N15/113 ,  C12N15/1138 ,  C12N15/63 ,  C12N2310/10 ,  C12Q1/6876 ,  C12Q2600/158 ,  G01N30/04 ,  G01N2030/027

摘要： Mutated genome silencing with endogenous RNAi-siRNA and miRNA with near total cellular apheresis with pulse flow apheresis system and EV-exosome-RNA molecular apheresis with sucrose density gradient continuous flow ultracentrifugation combined with array centrifuge for both 50S higher and 50S lower proteomics and genomics apheresis and their fractionated purification with immobilized Tim4-Fc protein Ca2+ magnetic beads affinity chromatography (ACG) and immobilized metal ACG is disclosed. It purifies normal cell derived and tumor cell derived EVs-exosomes, proteomics and subcellular particles. Tumor-specific endogenous siRNA is generated from mutated RNA containing pre-miRNA hairpin through RNA-induced silencing complex (RISC) composed of Dicer, dsRNA binding protein TRBP, and AGO2. Incubating purified RSIC with pre-let-7 hairpin generates siRNA. SiRNA is bonded with T-EVs and T-cells to silence its evasion from tumor immunity. While on radiation therapy or surgery, a patient's blood is continuously processed with above systems. It delivers combined online radiotherapy, and tumor-seeking adoptive extracorporeal chemo-immunotherapy.

公开(公告)号：US20180245099A1

公开(公告)日：2018-08-30

申请号：US15965921

申请日：2018-04-28

申请人： Caribou Biosciences, Inc.

发明人： Paul Daniel Donohoue ,  Andrew Paul May

IPC分类号： C12N15/87 ,  C12N15/113 ,  C12N9/22 ,  C12N9/96 ,  C12N15/11

CPC分类号： C12N15/87 ,  C12N9/22 ,  C12N9/96 ,  C12N15/111 ,  C12N15/113 ,  C12N2310/10 ,  C12N2310/20 ,  C12N2310/3513 ,  C12N2310/531

摘要： The present specification discloses engineered Type II CRISPR-Cas9 systems comprising split-nexus Cas9-associated polynucleotides (sn-casPNs), including systems comprising three split-nexus Cas9-associated polynucleotides (sn1-casPN/sn2-casPN/sn3-casPN) and systems comprising two split-nexus Cas9-associated polynucleotides (sn1-casPN/sn2-casPN). Together with a Cas9 protein, the sn-casPNs facilitate site-specific modifications, including cleavage and mutagenesis, of a target polynucleotide in vitro and in vivo. Furthermore, the engineered Type II CRISPR-Cas9 systems comprising sn-casPNs are useful in methods of regulating expression of a target nucleic acid. Methods are described herein for the creation of a variety of engineered Type II CRISPR-Cas9 systems comprising two or more sn-casPNs. Polynucleotide sequences, expression cassettes, vectors, compositions, and kits for carrying out a variety of methods are also described. Furthermore, the present specification provides genetically modified cells, compositions of modified cells, transgenic organisms, pharmaceutical compositions, as well as a variety of compositions and methods involving the engineered Type II CRISPR-Cas9 systems.

公开(公告)号：US10053688B2

公开(公告)日：2018-08-21

申请号：US15682100

申请日：2017-08-21

申请人： Twist Bioscience Corporation

发明人： Anthony Cox ,  Siyuan Chen

IPC分类号： C12N15/10 ,  C12Q1/68 ,  C40B40/06 ,  C12Q1/6806 ,  C12Q1/6816

CPC分类号： C12N15/1068 ,  C12N15/1093 ,  C12N15/111 ,  C12N2310/10 ,  C12N2310/20 ,  C12N2330/31 ,  C12Q1/6806 ,  C12Q1/6816 ,  C40B40/06

摘要： Disclosed herein are methods for the generation of nucleic acid libraries encoding for gRNA sequences. The gRNAs encoded by methods described herein may be single or double gRNA sequences. Methods described provide for the generation of gRNA libraries, as a DNA precursor or as a RNA transcription product, with improved accuracy and uniformity.

公开(公告)号：US20180179523A1

公开(公告)日：2018-06-28

申请号：US15881684

申请日：2018-01-26

申请人： INTEGRATED DNA TECHNOLOGIES, INC.

发明人： Michael Allen Collingwood ,  Ashley Mae Jacobi ,  Garrett Richard Rettig ,  Mollie Sue Schubert ,  Mark Aaron Behlke ,  Christopher Anthony Vakulskas ,  Rolf Turk

IPC分类号： C12N15/11

CPC分类号： C12N15/111 ,  C12N2310/10 ,  C12N2310/20 ,  C12N2310/315 ,  C12N2310/317 ,  C12N2310/3183 ,  C12N2310/321 ,  C12N2310/322 ,  C12N2310/3231 ,  C12N2310/346 ,  C12N2310/3521 ,  C12N2310/3533 ,  C12N2310/531 ,  C12N2320/51 ,  C12N2320/53

摘要： This invention pertains to modified compositions for use in CRISPR systems, and their methods of use. In particular, length-modified and chemically-modified forms of crRNA are described for use as a reconstituted guide RNA for interaction with Cas9 of CRISPR systems. The resultant length-modified and chemically-modified forms of crRNA are economical to produce and can be tailored to have unique properties relevant to their biochemical and biological activity in the context of the CRIPSR Cas9 endonuclease system.

公开(公告)号：US20180171028A1

公开(公告)日：2018-06-21

申请号：US15573702

申请日：2016-05-13

申请人： Zumutor Biologics, Inc.

发明人： Sohang Chatterjee ,  Kavitha Iyer Rodrigues ,  Maloy Ghosh ,  Sunit Maity ,  Divya Unnikrishnan ,  Jahnabi Hazarika ,  Yogendra Manjunath Bangalore Muniraju ,  Sathyabalan Murugesan ,  Pavithra Mukunda ,  Bhargav Prasad ,  Veeresha Kamanagowda ,  Sanghamitra Bhattacharjee ,  Pravin Kumar Dakshinamurthy ,  Vivek Halan ,  Sankaranarayanan Srinivasan ,  Anuradha Hora ,  Bairavabalakumar Natarajan ,  Karthika Nair ,  Aswini Thanigaivel ,  Amol Maliwalave ,  Bharath Ravindra Shenoy ,  Sahana Bhima Rao ,  Subhra Prakash Chakrabarty ,  Ashvini Kumar Dubey ,  Amir Khan ,  Ankurina Sharma

IPC分类号： C07K16/32 ,  C12N15/113 ,  C12N9/22 ,  C12N15/90

CPC分类号： C07K16/32 ,  C07K16/065 ,  C07K2317/14 ,  C07K2317/41 ,  C07K2317/73 ,  C07K2317/732 ,  C07K2317/76 ,  C12N9/22 ,  C12N15/1137 ,  C12N15/907 ,  C12N2310/10 ,  C12N2310/20 ,  C12N2800/80 ,  C12Y204/01068

摘要： The present disclosure relates to methods of obtaining cell with disrupted fucosylation and obtaining afucosylated protein. The present disclosure employs the Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) technology in a protein producing cell line to produce afucosylated protein. The resulting protein, specifically the resulting monoclonal antibody is completely afucosylated and reveals higher degree of antibody dependent cellular cytotoxicity.

公开(公告)号：US09982278B2

公开(公告)日：2018-05-29

申请号：US15630909

申请日：2017-06-22

申请人： THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE

发明人： Ryan T. Gill ,  Andrew Garst

IPC分类号： C12N15/09 ,  C12N15/90 ,  C12N15/10 ,  C12N15/11 ,  C12N9/22 ,  C12N15/63 ,  C12N15/64 ,  C12N15/70 ,  C12N15/74 ,  C12N15/79 ,  C12N15/81 ,  C12N15/82 ,  C12N15/85

CPC分类号： C12N15/902 ,  C12N9/22 ,  C12N15/102 ,  C12N15/1024 ,  C12N15/1082 ,  C12N15/1093 ,  C12N15/11 ,  C12N15/111 ,  C12N2310/10 ,  C12N2310/20 ,  C12N2320/11 ,  C12N2320/12 ,  C12N2330/31 ,  C40B40/08

摘要： Described herein are methods and vectors for rational, multiplexed manipulation of chromosomes within open reading frames (e.g., in protein libraries) or any segment of a chromosome in a cell or population of cells, in which various CRISPR systems are used.

公开(公告)号：US20180051281A1

公开(公告)日：2018-02-22

申请号：US15607295

申请日：2017-05-26

申请人： Agilent Technologies, Inc.

发明人： Daniel E. Ryan ,  Douglas J. Dellinger ,  Jeffrey R. Sampson ,  Robert Kaiser ,  Joel Myerson

IPC分类号： C12N15/11 ,  C12N9/22 ,  C12N15/113 ,  C12N2310/20

CPC分类号： C12N15/111 ,  C07H21/02 ,  C12N9/22 ,  C12N15/113 ,  C12N15/907 ,  C12N2310/10 ,  C12N2310/20 ,  C12N2310/312 ,  C12N2310/315 ,  C12N2310/321 ,  C12N2310/322 ,  C12N2310/323 ,  C12N2310/3231 ,  C12N2310/333 ,  C12N2310/335 ,  C12N2310/346 ,  C12N2310/3517 ,  C12N2310/531 ,  C12N2320/51 ,  C12N2320/53 ,  C12N2330/31 ,  C12Q1/6876 ,  C12N2310/3521 ,  C12N2310/3533

摘要： The present invention relates to modified guide RNAs and their use in clustered, regularly interspaced, short palindromic repeats (CRISPR)/CRISPR-associated (Cas) systems.

公开(公告)号：US20180051278A1

公开(公告)日：2018-02-22

申请号：US15682100

申请日：2017-08-21

申请人： Twist Bioscience Corporation

发明人： Anthony COX ,  Siyuan CHEN

IPC分类号： C12N15/10 ,  C12Q1/68

CPC分类号： C12N15/1068 ,  C12N15/1093 ,  C12N2310/10 ,  C12N2310/20 ,  C12Q1/6806 ,  C12Q1/6816 ,  C40B40/06

摘要： Disclosed herein are methods for the generation of nucleic acid libraries encoding for gRNA sequences. The gRNAs encoded by methods described herein may be single or double gRNA sequences. Methods described provide for the generation of gRNA libraries, as a DNA precursor or as a RNA transcription product, with improved accuracy and uniformity.

公开(公告)号：US20170335331A1

公开(公告)日：2017-11-23

申请号：US15516240

申请日：2015-10-15

申请人： THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA

发明人： Yangbing Zhao ,  Jiangtao Ren ,  Xiaojun Liu ,  Carl H. June

IPC分类号： C12N15/113 ,  A61K35/26 ,  A61K39/00 ,  C12N15/85 ,  A61K35/17 ,  C12N2310/20

CPC分类号： C12N15/1138 ,  A61K35/17 ,  A61K35/26 ,  A61K39/0011 ,  A61K2039/5156 ,  A61K2039/5158 ,  A61P35/00 ,  A61P37/06 ,  C12N15/85 ,  C12N2310/10 ,  C12N2310/20 ,  C12N2501/48 ,  C12N2501/515 ,  C12N2501/599 ,  C12N2501/998 ,  C12N2510/00

摘要： The present invention relates to compositions and methods for generating a modified T cell with a nucleic acid capable of downregulating endogenous gene expression selected from the group consisting of TCR α chain, TCR β chain, beta-2 microglobulin, a HLA molecule, CTLA-4, PD1, and FAS and further comprising a nucleic acid encoding a modified T cell receptor (TCR) comprising affinity for a surface antigen on a target cell or an electroporated nucleic acid encoding a chimeric antigen receptor (CAR). Also included are methods and pharmaceutical compositions comprising the modified T cell for adoptive therapy and treating a condition, such as an autoimmune disease.

公开(公告)号：US20170314015A1

公开(公告)日：2017-11-02

申请号：US15129367

申请日：2015-03-26

申请人： EDITAS MEDICINE, INC.

发明人： Ari E. FRIEDLAND ,  Morgan L. MAEDER ,  G. Grant WELSTEAD ,  David A. BUMCROT

IPC分类号： C12N15/11 ,  C12N15/10 ,  C12N9/22 ,  A61K48/00 ,  C12N2310/20

CPC分类号： C12N15/11 ,  A61K48/005 ,  C12N9/22 ,  C12N15/1024 ,  C12N15/113 ,  C12N2310/10 ,  C12N2310/20 ,  C12N2320/34

摘要： CRISPR/CAS-related compositions and methods for treatment of Sickle Cell Disease (SCD) are disclosed.